Susceptibility in vitro of canine methicillin-resistant and -susceptible staphylococcal isolates to fusidic acid, chlorhexidine and miconazole: opportunities for topical therapy of canine superficial pyoderma

The Journal of Antimicrobial Chemotherapy
S M ClarkR Bond

Abstract

Increasing multidrug resistance amongst canine pathogenic staphylococci has renewed interest in topical antibacterial therapy for skin infections in the context of responsible veterinary prescribing. We therefore determined the activity in vitro of three clinically relevant topical agents and synergism between two of them against Staphylococcus pseudintermedius and Staphylococcus aureus. The MICs of fusidic acid (n = 199), chlorhexidine (n = 198), miconazole (n = 198) and a 1:1 combination of miconazole/chlorhexidine (n = 198) were determined for canine isolates [50 MRSA and 49 methicillin-resistant S. pseudintermedius (MRSP), 50 MSSA and 50 methicillin-susceptible S. pseudintermedius (MSSP)] collected from the UK and Germany using an agar dilution method (CLSI VET01-A4). Fractional inhibitory concentration (FIC) indices were calculated to assess the interaction of miconazole with chlorhexidine. MICs of each drug/combination were significantly (P < 0.0005) higher for S. aureus when compared with S. pseudintermedius. Most strains (n = 172) had an MIC of fusidic acid of ≤0.03 mg/L (MIC ≥64 mg/L, n = 5 MRSA). All strains had MICs of chlorhexidine of 0.5-4 mg/L, except for one MRSA (MIC = 8 mg/L). All but four strains had MICs of m...Continue Reading

References

Feb 13, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·UNKNOWN European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and In
Mar 13, 2002·Lancet·Erwin M Brown, Paul Thomas
Jun 14, 2003·The Journal of Antimicrobial Chemotherapy·F C Odds
Sep 30, 2008·The Journal of Antimicrobial Chemotherapy·A LoefflerD H Lloyd
Apr 29, 2010·Veterinary Research·Ricardo Jorge Soares MagalhãesDirk Udo Pfeiffer
May 13, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David J FarrellIan Chopra
Jul 27, 2012·The Journal of Antimicrobial Chemotherapy·Carolyne HornerMark Wilcox

❮ Previous
Next ❯

Citations

Sep 24, 2016·The Journal of Antimicrobial Chemotherapy·Stefan SchwarzEngeline van Duijkeren
Nov 11, 2015·Antimicrobial Agents and Chemotherapy·Teresa ConceiçãoMarta Aires-de-Sousa
Dec 4, 2021·Tierärztliche Praxis. Ausgabe K, Kleintiere/Heimtiere·Anette LoefflerSiân-Marie Frosini

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.